MRS (magnetic resonance spectroscopy) set to get Medicare "no" for brain tumours
This article was originally published in Clinica
Executive Summary
The Centers for Medicare & Medicaid Services (CMS) is expected to decide against coverage of magnetic resonance spectroscopy (MRS) for brain tumours, based on the findings of a new technology assessment it released last week.